• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Real Estate·BRE.TO
Share

Bridgemarq Real Estate Services Inc. Stocks

CA$ 4.21Last Updated 07.08.2026

Issuer Rating

5/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

CA$ 28.65M

CA$ 4.21
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bridgemarq Real Estate Services Inc. provides comprehensive support to residential real estate brokers and REALTORS throughout Canada. The firm furnishes its clients with vital information, practical tools, and a suite of services designed to enhance their delivery of real estate sales. Operating under the distinguished Royal LePage, Via Capitale, and Johnston & Daniel brand names, its extensive franchise network, as of December 31, 2021, included 20,159 REALTORS, operating through 281 franchise agreements across 723 locations. The company, which transitioned from its former name Brookfield Real Estate Services Inc. in May 2019, was incorporated in 2010 and is headquartered in Toronto, Canada.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA, underpriced o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.08.2026 17:25

Mid-cap biotech stocks soared on the back of successful trials of a hot flash treatment

11.08.2026 16:55

The price of gold rose above $4,400. Citadel identified a rare combination of factors driving the rise

11.08.2026 16:30

Biotech firm Sionna unexpectedly failed its drug trials and lost 90% of its value in a single day

11.08.2026 16:08

Brent crude has approached $90. An analyst warned of the risk of a price spike as early as next week

11.08.2026 15:27

Morning in New York: Stock Indices Near All-Time Highs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026